**In Silico Screening of Bioactive Compounds from Syzygium cumini L. and Moringa oleifera L. Against SARS-CoV-2 via Tetra Inhibitors**

Nur Sofiatul Aini1, Vio Dhea Kharisma1, Muhammad Hermawan Widyanaanda1,2, Ahmad Affan Ali Murtado1,2, Rasyadan Taufiq Probojati1,3, Dora Dayu Rahma Turista1,2, Muhammad Badrul Tamami1, Vikash Jakhmo1,2, Devni Prima Sar1,3, Muhammad Toriq Albar1,10, Devi Pernamasari1,11, Muhammad Arya Ghifari1,9, Muhammad Raffi Ghifari1,10, Riso Sari Mandeli11,12, Muhadi13,14, Budhi Oktavia1,15, Trisna Kumala Sar11,16, Titri Sriwahyuni1,15, Putri Azhari18,16, Mirella Fonda Maahury17,16, ANM Ansori18, Rahadian Zainul14,19

**ABSTRACT**

The global pandemic of COVID-19 has caused disastrous consequences for both humans and the economy. The purpose of this study was to determine the potential of juvet (Syzygium cumini L.) and moringa (Moringa oleifera L.) as inhibitors of RBD spike, helicase, Mpro, and RdRp activity of SARS-CoV-2 with an *in-silico* approach. Samples were obtained from PubChem and RSCB PDB databases. The drug similarity analysis was determined using Swiss ADME and the Lipinski rule of five. Prediction of antiviral probabilities is carried out using Swiss ADME and the Lipinski rule of five. The bioactive compounds with the best antiviral potential had the lowest affinity bonds to the target proteins against RBD spike, helicase, Mpro, and RdRp of SARS-CoV-2. Results show that 5-67% from java plum and myricetin from moringa have the best potential as potential antivirals. However, more research is required to validate the results of these computational predictions.

**Key words:** SARS-CoV-2, Syzygium cumini L., Moringa oleifera L., In silico, Antiviral agent.

**INTRODUCTION**

Severe acute coronavirus-2 (SARS-CoV-2) causes coronavirus disease (COVID-19). This disease spread rapidly throughout the world, resulting in a pandemic. According to WHO, there are more than 50 million confirmed cases and more than 6.3 million deaths worldwide due to COVID-19 infection as of July 12, 2022. SARS-CoV-2 is an enveloped, positive sense, single-stranded RNA virus that causes human infection. So far, there are seven human coronaviruses have been identified: HCoV-OC43, HCoV-229E, HCoV-HKU1, HCoV-NL63, SARS-CoV, MERS-CoV, and SARS-CoV-2. SARS-CoV, MERS-CoV and SARS-CoV-2 have the most widespread spread and infection. Genome analysis showed that SARS-CoV-2 matched 79.5% with the SARS-CoV virus that had become an epidemic in 26 countries by 2003.

SARS-CoV-2 infection in human cells occurs mediated by receptor binding domain (RBD) spike with angiotensin-converting enzyme 2 (ACE-2). Viral RNA helices are involved in RNA replication. Furthermore, viral RNA undergoes translations producing pp1a and pp1ab proteins which are then folded by proteolytic enzymes such as Mpro. RdRp binds to RNA genome (negative-sense) to form genome and subgenome RNA (positive sense) via replication and transcription.

Synthesis inhibitors have been discovered in some studies. However, there are some side effects caused to the body after taking the drug. Bioactive compounds derived from medical plants in Indonesia are expected to be able to provide antiviral compounds against SARS-CoV-2. Java plum and moringa are two Indonesian plants that can be used in medicine. Java plum (Syzygium cumini L.) is a plant in the Myrtaceae family. The plant is indigenous to India and distributed in tropical Asia and Australia. In Indonesia, java plum is typically consumed directly or mixed with food. Juwet has been shown to have antiviral activity against avian influenza virus (H5N1). Meanwhile, moringa (Moringa oleifera L.) is a plant in the Moringaceae family. Moringa is indigenous to North India and can be cultivated in tropical and subtropical climates. This plant is used in traditional Indonesian drinks and may have antiviral properties against hepatitis B (HBV). However, the potential of the two plants as anti-SARS-CoV-2 remains unclear.

The study of SARS-CoV-2 inhibitor compounds takes a time, but preliminary research to determine the potential of plants as drug candidates can be approached with an *in-silico* approach. As a result, this study aims to determine the potential of java plum and moringa as inhibitors of RBD spike, helicase, Mpro, and RdRp activity of SARS-CoV-2 in *silico*.

**MATERIALS AND METHODS**

**Sample preparation**

The components of the bioactive ligands found in juwet and moringa are gallic acid (CID: 370), ellagic acid (CID: 5281855), corilagin (CID: 73568), moringine (CID: 131751186), myricetin (CID: 5281672), chlorogenic acid (CID: 1794427), vextin (CID: 5280441), and nirmatrelvir (CID: 155903259) as a control. Ligand structure data were obtained

**Cite this article:** Aini NS, Kharisma VD, Widyanaanda MH, Murtadio AAA, Probojati RT, Turista DDR, et al. *In Silico Screening of Bioactive Compounds from Syzygium cumini L. and Moringa oleifera L. Against SARS-CoV-2 via Tetra Inhibitors*. Pharmacogn J. 2022;14(4): 267-272.
Drug-likeness analysis

Bioactive compounds from Moringa and juwet were analyzed for similarities in the drug using the SwissADME web. The Lipinski’s rule of was used including molecular weight of <500 Da, hydrogen donor bond (HBD) <5, hydrogen acceptor bond (HBA) <10, high lipopolysis (LogP) <5, and molar refractory (MR) 40-130. Positive predictions were characterized by at least 2 rules. This analysis aimed to determine the probability of a candidate drug molecule passing through the cell membrane if the target is in the cytoplasm and pharmacokinetics.

Antiviral probability prediction

Bioactivity prediction is carried out using the PASS Online web. The category of predictions sought is antiviruses. The potential activity standards used are Pa scores >0.3 and Pa > Pi. This score is favored as computational proof in molecular docking.
Virtual screening

Docking simulations were carried out to determine the intermolecular energy that binds. Molecular docking was carried out with PyRx because of its high accuracy.20 This was done to determine the activity between ligands and receptors in SARS-CoV-2 which is critical in COVID-19 infection. The purpose of molecular docking is to identify the binding energy of bioactive compounds to target proteins as anti-SARS-CoV-2.27,28

Interaction and visualization

Visualization aims to describe the results of docking in more detail. Visualized compounds are the compounds with the lowest binding affinity. Visualization is done using PyMol and Discovery Studio. The result of visualization with PyMol is ligand-target protein complexes.29 Meanwhile, interactions were visualized with Discovery Studio.

RESULT AND DISCUSSION

Lipinski rule of five is important for determining compounds such as drug candidate molecules. In this study, it was found that there are 5 bioactive compounds that match Lipinski rules of five, namely: chlorogenic acid, gallic acid, ellagic acid, moryngine, and myricetin. The PASS Online analysis results show that all drug candidate compounds have good activity (Table 1). However, this prediction still requires in vivo and in vitro analysis to confirm the antiviral potential of bioactive compounds further.24

The molecular docking results aim to determine the stability interaction between the ligand and the target protein. The lowest binding affinity indicates the maximum level of stable interaction indicating that the ligand inhibitory activity against the target protein is larger.31,32 All bioactive compounds have activity against target proteins (Table 2). However, the compounds to be analyzed next are those with the lowest binding affinity and that follow Lipinski rules of five.

Myricetin and ellagic acid are such compounds. The SARS-CoV-2 RBD spike has more extensive amino acid residue conservation that can be used as binding key sites in molecular docking such as glutamine (Gln), cysteine (Cys), histidine (His), and aspartic acid (Asp).33 Myricetin has no hydrogen or hydrophobic bonds to conservative residues. However, it forms hydrogen and hydrophobic bonds with other amino acid residues. Meanwhile, ellagic acid has one vdW hydrophobic interaction with Gln98. Hydrogen bonds cause the resulting binding affinity to be more negative, thus stabilizing the interaction of myricetin and ellagic acid with the SARS-CoV-2 RBD spike.34 Furthermore, the presence of weak hydrophobic interactions such as Pi-alkyl, Pi-sigma, and vdW bonds aids the stability and turnover of interactions between ligands and target proteins in cellular processes.35

SARS-CoV-2 helicase is involved in RNA replication.11,12 Some helicase segments of SARS-CoV-2 variants show similarities to the S' RNA NSP13 site, indicating that the part has great potential as a docked part in the development of anti-SARS-CoV-2.12,36 Myricetin and ellagic acid have a variety of bonds, including hydrogen bonds, pi-sigma, pi-alkyl, and vdW interactions. The presence of pi-anion bonds in ellagic acid aids the stability interaction with helicase so that the binding affinity is more negative.27 Both compounds bind to amino acid residues in domain I of helicase which plays a role in the introduction of nucleic acids.36

Mpro is a cysteine protease responsible for viral maturation and protein folding.13,14,39 SARS-CoV-2 variants are so conserved, there are no homologs in humans, and have low mutation rate.40 Some of these conserved sites are catalytic residues consisting of asparagine (Asn), glutamine (Gln), and proline (Pro).41 This position can be used for molecular docking in the development of multivariate anti-SARS-CoV-2. Based on the docking results, myricetin has no binding to catalytic residues so it has a more positive affinity bond than ellagic acid. However, there are other hydrogen and hydrophobic bonds to other residual amino acids that stabilize the interaction of myricetin with Mpro. In addition, there is a less preferred bond to Arg60 that requires further research into its role in this interaction.34 Meanwhile, ellagic acid likely has bonds with some catalytic residues such as hydrogen bonds with Gln110 as well as vdW bonds with Gln107 and Asn151. RdRp is essential for coronavirus replication and transcription.13,16,43 RdRp is assisted in this role by other proteins such as nsp7 and nsp8.44,45

Table 1: Lipinski rule of five and antiviral probability of selected compounds from java plum and moringa.

| Plant                   | Compound | MW      | HBD | HBA | LogP | MR    | Antiviral Probability |
|-------------------------|----------|---------|-----|-----|------|-------|-----------------------|
| Syzygium cumini L.      | Gallic   | 170.12  | 4   | 5   | 0.21 | 39.47 | 0.342                 |
|                         | Ellagic  | 302.19  | 8   | 4   | 1.00 | 75.31 | 0.322                 |
|                         | Corilagin| 634.45  | 18  | 11  | -0.55| 141.85| 0.348                 |
|                         | Moryngine| 312.32  | 4   | 7   | 0.07 | 75.31 | 0.345                 |
|                         | Myricetin| 318.24  | 6   | 8   | 0.79 | 80.06 | 0.334                 |
|                         | Chlorogenic acid | 354.31  | 6   | 9   | -0.38| 83.50 | 0.303                 |
|                         | Vitexin  | 634.45  | 11  | 18  | -0.55| 141.85| 0.360                 |

Table 2: Binding affinity (kcal/mol) ligand-protein complexes.

| Plant                   | Compound | Binding Affinity (kcal/mol) |
|-------------------------|----------|----------------------------|
|                         | RDB Spike| Helicase                   |
|                         | Mpro     | RdRp                       |
| Syzygium cumini L.      | Nirmatrelvir | -7.9                      |
|                         | Gallic   | -6.2                      |
|                         | Ellagic  | -8.7                      |
|                         | Corilagin| -9.4                      |
|                         | Moryngine| -7.1                      |
|                         | Myricetin| -8.5                      |
|                         | Chlorogenic acid | -7.7                      |
|                         | Vitexin  | -8.8                      |
| Moringa oleifera L.     | Nirmatrelvir | -7.9                      |
|                         | Gallic   | -6.2                      |
|                         | Ellagic  | -8.7                      |
|                         | Corilagin| -9.4                      |
|                         | Moryngine| -7.1                      |
|                         | Myricetin| -8.5                      |
|                         | Chlorogenic acid | -7.7                      |
|                         | Vitexin  | -8.8                      |
Many conservative catalytic residues in this protein have the potential to bind to docked bioactive compound ligands.47-52 The majority of such residues are serine (Ser) and glycine (Gly).4 According to the results of molecular docking, myricetin has a vdW bond with catalytic residual amino acids Ser709, Gly774, and Ser784. Meanwhile, ellagic acid has hydrogen bonds with Gly774 and Ser784 and vdW bonds with Ser778. The presence of hydrogen bonds in catalytic residues aids in the stabilization of the ligands-target protein complexes, resulting in the desired interaction conformation.

CONCLUSION

The combination of the bioactive compound’s java plum (Syzygium cumini L.) and moringa (Moringa oleifera L.) has the potential to be anti-SARS-CoV-2. Myricetin and ellagic acid are known to have the lowest binding affinity to RDB spike, helicase, Mpro, and RdRp of SARS-CoV-2. However, more research is needed to support the results of this study.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest.

REFERENCES

1. Fahmi M, Kharisma VD, Ansori ANM, Ito M. Retrieval and investigation of data on SARS-CoV-2 and COVID-19 using bioinformatics approach. Adv Exp Med Biol. 2021;1318:839-57.
2. Turista DDR, Islamy A, Kharisma VD, Ansori ANM. Distribution of COVID-19 and phylogenetic tree construction of SARS-CoV-2 in Indonesia. J Pure Applied Microbiol. 2020;10:1036-42.
3. Ansori ANM, Kusala MKJ, Irawan H, Putri N, Fadholly A, Probojati RT, Widyananda MH, Parikesit AA. Severe Acute Respiratory Syndrome Coronavirus 2 Emergence and Its Treatment with Alternative Medicines: A Review. J R Pharma Technol. 2021;14(10):8551-7.
4. Ansori ANM, Kharisma VD, Fadholly A, Tacharina MR, Antonius Y, Parikesit AA. Severe Acute Respiratory Syndrome Coronavirus 2 and Its Treatment with Alternative Medicines: A Review. J R Pharmacy Technol. 2021;14(10):8551-7.
5. Hafidzah MA, Wijaya RM, Probojati RT, Kharisma VD, Ansori AN, Probojati RT. Potential vaccine targets for COVID-19 and phylogenetic analysis based on the nucleocapsid phosphoprotein of Indonesian SARS-CoV-2 isolates. Indonesian J Pharm. 2021;32(3):328-37.
6. Ansori ANM, Kharisma VD, Muttaqin SS, Antonius Y, Parikesit AA. Genetic variant of SARS-CoV-2 isolates in Indonesia: Spike glycoprotein gene. J Pure Applied Microbiol. 2020;14(11):971-8.
7. Wijaya RM, Hafidzah MA, Kharisma VD, Ansori ANM, Parikesit AA. COVID-19 in silico drug with Zingiber officinale natural product compound library targeting the Mpro protein. Makara J Sci. 2021;25(3):162-71.
8. Hartono, Suryawati B, Sari Y, Avicena A, Maryani, Sukmagautama C, et al. The effect of curcumin and virgin coconut oil towards cytokines levels in COVID-19 patients at Universitas Sebelas Maret Hospital, Surakarta, Indonesia. Pharmaco. J 2022;14(11):216-25.
9. Parikesit AA, Nurdiansyah R. Natural products repurposing of the H5N1-based lead compounds for the most fit inhibitors against 3C-like protease SARS-CoV-2. J Pharm Pharmacol Res. 2021;9(5):730-45.
10. Risky WC, Jhivapran MC, Kindi AA, Ansori ANM, Mustaq M. The pharmacological mechanism of quecetin as adjuvant therapy of COVID-19. Traditional Med Res. 2020;2022:1-9.
11. Kharisma VD, Ansori AN, Probojati RT, Turista DD, Antonius Y. Concept of SARS-CoV-2 Vaccine Design to Fight COVID-19 Pandemic: A Review Insight. Indian J Forensic Med Toxicol. 2021;15(4):2797-803.
12. Dibha AF, Wahyuingsih S, Kharisma VD, Ansori AN, Widyananda MH, Parkesit AA, et al. Biological activity of kencur (Kaempferia galanga L.) against SARS-CoV-2 main protease: In silico study. Int J Health Sci. 2022;6(5):478-80.
13. Muttaqin SS, Ansori ANM. Candidate inhibitors of SARS-CoV-2 main protease with 3D structure similar to N3. Res J Biotechnol. 2020;15(11):55-9.
14. Song Y, Peng W, Tang D, Dai Y. Protease inhibitor use in COVID-19. SN Comprehensive Clin Med. 2020;2(9):1436-43.
15. Venkataraman S, Prasad BVLS, Selvarajan R. DNA dependent RNA polymerases: Insights from structure, function and evolution. Viruses. 2018;10(2):76.
16. Ansori ANM, Antonius Y. A phylogenetic analysis of Indonesian SARS-CoV-2 isolates from March to December 2020: Compared with Delta and Mu variant. Jurnal Teknologi Laboratorium. 2022;1(11).
17. Tavares IMdC, Lago-Vanzela ES, Rebello LPG, Ramos AM, Gómez-Alonso S, García-Romero E, et al. Comprehensive study of the phenolic composition of the edible parts of jambolan fruit (Syzygium cumini (L.) Skeels). Food Res Int. 2016;82:1-13.
18. Sood R, Swarup D, Bhatia S, Kulkarni D, Dey S, Saini M, et al. Antiviral activity of crude extracts of Eugenia jambolana Lam. Against highly pathogenic avian influenza (H5N1). Indian J Exp Biol. 2012;50(3):179-86.
19. Razis AFA, Ibrahim MD, Kntayya SB. Health benefits of Moringa oleifera. Asian Pac J Cancer Prev. 2014;15(20):8571-6.
20. Ansori ANM, Fadholly A, Probolingrat A, Antonius Y, Hayaza S, Susilo JR. Novel Antiviral Investigation of Annona squamosa Leaf Extract against the Dengue Virus Type-2: In vitro Study. Pharmaco. J 2021;13(2):456-62.
21. Kharisma VD, Ansori ANM, Nugraha AP. The effect of curcumin and virgin coconut oil towards SARS-CoV-2 via Tetra Inhibitors. Adv Exp Med Biol. 2021;1318:839-57.
22. Kharisma VD, Widyananda MH, Ansori ANM, Nege AS, Nawi SW, Nugraha AP. Tea catechin as antiviral agent via apoptosis agonist and triple inhibitor mechanism against HIV-1 infection: A bioinformatics approach. J Pharm Pharmacogn. 2021;9(4):435-45.
23. Kharisma VD, Ansori ANM, Dion FA, Rizky WC, Dings TGA, Zainul R, et al. Molecular docking and dynamics simulation of entry inhibitor from Tamarindus indica bioactive compounds against SARS-CoV-2 infection via viroinformatics study. Biochem Cell Arch. 2021;21(2):3323-7.
24. Ansori ANM, Kharisma VD, Probojati RT, Rebezov M, et al. Bioactive compounds from manguosteen (Garcinia mangostana L.) as an antiviral agent via individual inhibitor mechanism against SARS-CoV-2: An in-silico approach. Pharmacogn J. 2022;14(1):85-90.
25. Widyananda MH, Pratama SK, Sarnoeda RS, Sari FN, Kharisma VD, Ansori ANM, et al. Molecular docking study of sea urchin (Arbacia lixula) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins. J Pharm Pharmacogn Res. 2021;13(4):376-88.
26. Kharisma VD, Ansori ANM, Construction of epitope-based peptide vaccine against SARS-CoV-2: Immunobioinformatics study. J Pure Appl Microbiol. 2020;14(1):999-1005.
In SiColo Screening of Bioactive Compounds from Syzygium cumini L. and Moringa oleifera L. Against SARS-CoV-2 via Tetra Inhibitors
Aini NS, et al.: In Silico Screening of Bioactive Compounds from Syzygium cumini L. and Moringa oleifera L. Against SARS-CoV-2 via Tetra Inhibitors

Pharmacogn J. 2022;14(4): 267-272.

Cite this article: Aini NS, Kharisma VD, Widyananda MH, Murtadlo AAA, Probojati RT, Turista DDR, et al. In Silico Screening of Bioactive Compounds from Syzygium cumini L. and Moringa oleifera L. Against SARS-CoV-2 via Tetra Inhibitors. Pharmacogn J. 2022;14(4): 267-272.